Review of recent results of montelukast use as a monotherapy in children with mild asthma

Clinical Therapeutics

Volumn 30, Issue PART 1, 2008, Pages 1026-1035

  Wahn, Ulrich ^a   Balachandra Dass, S ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

leukotriene receptor antagonist; mild asthma; montelukast; pediatric asthma; therapeutic options in asthma

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHROMONE DERIVATIVE; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; THEOPHYLLINE;

ADOLESCENT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXERCISE INDUCED ASTHMA; GROWTH RETARDATION; HUMAN; LUNG FUNCTION; MONOTHERAPY; PATIENT COMPLIANCE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACETATES; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; ASTHMA, EXERCISE-INDUCED; BRONCHOCONSTRICTION; CHILD; CHILD, PRESCHOOL; GLUCOCORTICOIDS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; LEUKOTRIENE ANTAGONISTS; PATIENT COMPLIANCE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47249151764     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.05.018     Document Type: Article

References (64)

1. van den Akker-van Marle M., Bruil J., and Detmar S. Evaluation of cost of disease: Assessing the burden to society of asthma in children in the European Union. Allergy 60 (2005) 140-149
2. Bloom B., and Dey A. Summary health statistics for US children: National Health Interview Survey, 2004. Vital Health Stat (2006) 1-85
3. Masoli M., Fabian D., Holt S., Beasley R., and for the Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 59 (2004) 469-478
4. Cloutier M., Hall C., Wakefield D., and Bailit H. Use of asthma guidelines by primary care providers to reduce hospitalizations and emergency departm ment visits in poor, minority, urban children. J Pediatr 146 (2005) 591-597
5. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), 2006 (2006), National Institutes of Health, Bethesda, Md. http://www.ginasthma.org Accessed April 24, 2008
6. Szefler S., and Apter A. Advances in pediatric and adult asthma. J Allergy Clin Immunol 115 (2005) 470-477
7. Martinez F. Development of wheezing disorders and asthma in preschool children. Pediatrics 109 (2002) 362-367
8. Bisgaard H. Persistent wheezing in very young preschool children reflects lower respiratory inflammation. Am J Respir Crit Care Med 163 (2001) 1290-1291
9. Illi S., von Mutius E., Lau S., et al., for the Multicentre Allergy Study (MAS) Group. Perennial allergen sensitisation early in life and chronic asthma in children: A birth cohort study [published correction appears in Lancet. 2006;368:1154]. Lancet 368 (2006) 763-770
10. Jartti T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?. Eur J Pediatr 167 (2008) 731-736
11. British Thoracic Society and Scottish Intercollegiate Guidelines Network. 2007 British Guideline on the Management of Asthma. http://www.sign.ac.uk/guidelines/fulltext/63/index.html Accessed April 24, 2008
12. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma, 2007 (2007), National Institutes of Health, Bethesda, Md. http://www.nhlbi.nih.gov/guidelines/asthma/ Accessed April 24, 2008
13. Lemanske Jr. R. Inflammation in childhood asthma and other wheezing disorders. Pediatrics 109 (2002) 368-372
14. Bisgaard H. Use of inhaled corticosteroids in pediatric asthma. Pediatr Pulmonol Suppl 15 (1997) 27-33
15. Bisgaard H., Hermansen M., Loland L., et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354 (2006) 1998-2005
16. Guilbert T., Morgan W., Zeiger R., et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354 (2006) 1985-1997
17. Gold D., and Fuhlbrigge A. Inhaled corticosteroids for young children with wheezing. N Engl J Med 354 (2006) 2058-2060
18. Allen D., Bielory L., Derendorf H., et al. Inhaled corticosteroids: Past lessons and future issues. J Allergy Clin Immunol 112 (2003) S1-S40
19. Pauwels R., Pedersen S., Busse W., et al., for the START Investigators Group. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet 361 (2003) 1071-1076
20. Peters S. Safety of inhaled corticosteroids in the treatment of persistent asthma. J Natl Med Assoc 98 (2006) 851-861
21. Finkelstein J., Lozano P., Shulruff R., et al. Self-reported physician practices for children with asthma: Are national guidelines followed?. Pediatrics 106 (2000) 886-896
22. Wolthers O., and Allen D. Inhaled corticosteroids, growth, and compliance. N Engl J Med 347 (2002) 1210-1211
23. Walders N., Kopel S., Koinis-Mitchell D., and McQuaid E. Patterns of quick-relief and long-term controller medication use in pediatric asthma. J Pediatr 146 (2005) 177-182
24. Jónasson G., Carlsen K., and Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 83 (2000) 330-333
25. Milgrom H., Bender B., Ackerson L., et al. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 98 (1996) 1051-1057
26. Guidelines on the management of asthma. Statement by the British Thoracic Society, the Brit. Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the Brit. Assoc. of Accident and Emergency Medicine, and the Brit. Paediatric Respiratory Group [published corrections appear in Thorax. 1994;49:386 and Thorax. 1994;49:96]. Thorax 48 Suppl 2 (1993) S1-S24
27. Kuehni C., and Frey U. Age-related differences in perceived asthma control in childhood: Guidelines and reality. Eur Respir J 20 (2002) 880-889
28. Carlton B., Lucas D., Ellis E., et al. The status of asthma control and asthma prescribing practices in the United States: Results of a large prospective asthma control survey of primary care practices. J Asthma 42 (2005) 529-535
29. Halterman J., Aligne C., Auinger P., et al. Inadequate therapy for asthma among children in the United States. Pediatrics 105 (2000) 272-276
30. Diette G., Skinner E., Markson L., et al. Consistency of care with national guidelines for children with asthma in managed care. J Pediatr 138 (2001) 59-64
31. Neffen H., Fritscher C., Schacht F., et al., for the AIRLA Survey Group. Asthma control in Latin America: The Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica 17 (2005) 191-197
32. Godfrey S. Asthma guidelines for children -are they useful?-No!. Pediatr Pulmonol Suppl 26 (2004) 447-448
33. Fabbri L., and Stoloff S. Is mild asthma really 'mild'?. Int J Clin Pract 59 (2005) 692-703
34. Galant S., Morphew T., Amaro S., and Liao O. Current asthma guidelines may not identify young children who have experienced significant morbidity. Pediatrics 117 (2006) 1038-1045
35. Bisgaard H., and Szefler S. Understanding mild persistent asthma in children: The next frontier. J Allergy Clin Immunol 115 (2005) 708-713
36. Peters S., Anthonisen N., Castro M., et al., for the American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma [published correction appears in N Engl J Med. 2007;357:728]. N Engl J Med 356 (2007) 2027-2039
37. Kemp J. Advances in the management of pediatric asthma: A review of recent FDA drug approvals and label updates. J Asthma 42 (2005) 615-622
38. Singulair (montelukast sodium) tablets, chewable tablets and oral granules, 2008 [prescribing information]. http://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.p df Accessed April 24, 2008
39. Electronic Medicines Compendium. Singulair Paediatric 4 mg granules, 2007. http://www.emc.medicines.org.uk/eMC/assets/c/html/DisplayDoc.asp?Documen tID=14071 Accessed April 24, 2008
40. Electronic Medicines Compendium. Singulair Paediatric 4 mg and 5 mg chewable tablets, 2007. http://www.emc.medicines.org.uk/eMC/assets/c/html/DisplayDoc.asp?Documen tID=17717 Accessed April 24, 2008.
41. Bjermer L. Montelukast in the treatment of asthma as a systemic disease. Expert Rev Clin Immunol 1 (2005) 325-336
42. Pedersen S., Agertoft L., Williams-Herman D., et al. Placebo-controlled study of montelukast and budesonide in short-term growth in pre-pubertal asthmatic children. Pediatr Pulmonol 42 (2007) 838-843
43. Becker A., Kuznetsova O., Vermeulen J., et al., for the Pediatric Montelukast Linear Growth Study Group. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone or placebo: A 56-week, randomized double-blind study. Ann Allergy Asthma Immunol 96 (2006) 800-807
44. Bisgaard H., Zielen S., Garcia-Garcia M., et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 171 (2005) 315-322
45. Knorr B., Franchi L., Bisgaard H., et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 108 (2001) E48
46. Knorr B., Matz J., Bernstein J., et al., for the Pediatric Montelukast Study Group. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial. JAMA 279 (1998) 1181-1186
47. Becker A., Swern A., Tozzi C., et al. Montelukast in asthmatic patients 6 years-14 years old with an FEV 1 >75%. Curr Med Res Opin 20 (2004) 1651-1659
48. Garcia Garcia M., Wahn U., Gilles L., et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC study [published correction appears in Pediatrics. 2005;116:1058]. Pediatrics 116 (2005) 360-369
49. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343 (2000) 1054-1063
50. Goodman D. When an asthma drug has an inferiority complex: A noninferiority trial. Pediatrics 116 (2005) 493-495
51. Szefler S., Phillips B., Martinez F., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005) 233-242
52. Baumgartner R., Martinez G., Edelman J., et al., for the Montelukast Asthma Study Group. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 21 (2003) 123-128
53. Israel E., Chervinsky P., Friedman B., et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 110 (2002) 847-854
54. Malmstrom K., Rodriguez-Gomez G., Guerra J., et al., for the Montelukast/Beclomethasone Study Group. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Ann Intern Med 130 (1999) 487-495
55. Juniper E., Guyatt G., Feeny D., et al. Measuring quality of life in children with asthma. Qual Life Res 5 (1996) 35-46
56. Gotshall R. Exercise-induced bronchoconstriction. Drugs 62 (2002) 1725-1739
57. Kemp J., Dockhorn R., Shapiro G., et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 133 (1998) 424-428
58. Kim J., Lee S., Kim H., et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol 39 (2005) 162-166
59. de Benedictis F., del Giudice M., Forenza N., et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 28 (2006) 291-295
60. Bukstein D., Bratton D., Firriolo K., et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: A randomized, open-label, crossover study. J Asthma 40 (2003) 475-485
61. Maspero J., Dueñas-Meza E., Volo-vitz B., et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: Results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 17 (2001) 996-1004
62. Davies G., Dasbach E., Santanello N., et al. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clin Ther 26 (2004) 1895-1904
63. Bukstein D., Luskin A., and Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma [published correction appears in Ann Allergy Asthma Immunol. 2003;91:308]. Ann Allergy Asthma Immunol 90 (2003) 543-549
64. Zeiger R., Szefler S., Phillips B., et al., for the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Response profiles to fluticasone and montelukast in mild-to-mmoderate persistent child-hood asthma. J Allergy Clin Immunol 117 (2006) 45-52